Downloads - meeting slides

Training session: ”The basics of drug development – the case for HCV“
Overview of drug development — what happens in phase I, phase II, phase III and post-marketing

Svilen Konov (London, UK) and Tracy Swan (New York, USA)

Epidemiology and natural history of HIV/HCV co-infection

Miguel de Melo, TRT-5, Paris, France

Natural history of liver disease in HCV-HIV co-infected patients: end-stage and post-transplantation

Josep Maria Miró, Hospital Clínic, Barcelona, Spain

Overview of drug development: regulatory agencies

FDA HCV trial design meeting: a report

Tracy Swan, Treatment Action Group, NYC, USA

EMEA perspective

Olle Karlström, Stockholm, Sweden

Spanish Agency of Drug and Health Products

Fernando de Andrés, Madrid, Spain

HCV : The path of least resistance in drug development

Raymond Schinazi, Emory University / Veteran Affairs Department, Atlanta, USA

Early access to HCV drugs: interactions, safety, efficacy

Bruce Polsky, St. Luke’s Hospital, NYC, USA

Limitations of current HCV treatment in co-infected populations: overview from the experience

Bruce Polsky, St. Luke’s Hospital, New York, USA
Massimo Puoti, Università degli Studi di Brescia, Italy
Carmen Tarrades, UK-CAB, UK
Diego García-Morcillo, FEAT, Spain